As COVID-19 continues to impact people around the globe, researchers are racing to develop vaccines and therapeutic options for the disease. Accurate animal models are essential for verifying the pathogenesis and immune mechanisms of the illness to accelerate development of vaccines and other drug-based interventions into the clinical trial stage.
When a virus invades a human host, the body will produce corresponding antibodies to neutralize the virus in order to reduce the virus's damage to the body and prevent it from invading cells by interacting with extracellular receptors. Animal models are widely used models for infectious diseases research, which makes it possible to analyze the human immune reaction to infection and increase the accuracy of preclinical test for a new vaccine.
Herein, we discuss how animal models may be used to advance your SARS-CoV-2 Neutralizing Antibody and Vaccine Research.
Download this Exclusive White Paper to discover how animal model are advancing SARS-CoV-2 Neutralizing Antibody and Vaccine Research.
Cyagen hACE2 Mice for COVID-19 Research
Cyagen uses the proprietary TurboKnockout® technology and optimized CRISPR-Pro Technology to carry out the development of humanized ACE2 (hACE2) mice across three background strains: BALB/c, C57BL/6J, and C57BL/6N. Our variety of hACE2 mouse model capabilities aim to meet the needs of different research applications for SARS-CoV-2 drug screening and vaccine development.
|Project Type||Background Strain||Genotype|
|Humanized ACE2 Mice||C57BL/6J||Heterozygous or Homozygous|
Cyagen now provides validation data reports of our humanized ACE2 mouse models for SARS-CoV-2 drug screening and vaccine development.